Medizinische Universitat Wien

Phadia Ab

Peter Steinberger

Johannes Kovarik

Florian Forster

David E Isenman

Margarethe Merio

Georg Böhmig

Markus Hölzl

Johannes Hofer

Judith Leitner

Gerhard Zlabinger

Markus Wahrmann

Rudolf Valenta

Dietrich Kraft

Sabine Flicker

Georg BÖHMIG

The present invention relates to a pharmaceutical composition comprising complement split product C4d for use in treating an inflammatory condition, such as graft rejection, graft versus host disease, an autoimmune disease or atopy. The C4d to be used may be a multimer. Accordingly, also C4d multimers and their use in medicine, like the treatment of inflammatory conditions, is provided. Furthermore, the present invention provides a protein complex comprising C4d interacting with its ILT4 receptor. This protein complex may be used in screening methods Also antibodies specifically binding to the C4d multimer or the C4d/ILT4-protein complex are subject of the present invention.

Complement split product C4d for the treatment of inflammatory conditions

The present invention relates to group 2 allergen specific IgE-Fabs and whole Ig molecules as well as use thereof. More precisely, the present invention relates to grass pollen specific IgE-Fabs (Phl p2) and reagents, kits and vaccines comprising these. The invention also relates to use of group 2 specific IgE-Fabs and whole Ig for, inter alia, diagnosis, therapy and prevention of type I allergy.

Group 2 allergen specific IgE-Fabs and use thereof

Growing community of inventors

Vienna, Austria

Peter Steinberger